Chronic corticosterone treatment increases the endocannabinoid 2-arachidonylglycerol in the rat amygdala. Eur J Pharmacol 2005 Dec 28;528(1-3):99-102
Date
12/06/2005Pubmed ID
16324692DOI
10.1016/j.ejphar.2005.10.058Scopus ID
2-s2.0-28844445664 (requires institutional sign-in at Scopus site) 35 CitationsAbstract
This research was designed to examine the effect of three weeks of administration of corticosterone (20 mg/kg) on endocannabinoid content and cannabinoid CB1 receptor binding in the amygdala. It was found that the endocannabinoid 2-arachidonylglycerol was significantly increased in the amygdala following chronic corticosterone treatment. However, there was no change in either the maximal binding (Bmax) or binding affinity (KD) of [3H]-CP 55,940 to the CB1 receptor in the amygdala. Given the role of amygdalar endocannabinoids in the regulation of emotionality, this suggests that the ability of glucocorticoids to influence affective behavior may involve interactions with regulation of endocannabinoid content.
Author List
Hill MN, Ho WS, Meier SE, Gorzalka BB, Hillard CJAuthor
Cecilia J. Hillard PhD Associate Dean, Center Director, Professor in the Pharmacology and Toxicology department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AmygdalaAnimals
Arachidonic Acids
Cannabinoid Receptor Modulators
Cannabinoids
Corticosterone
Cyclohexanols
Endocannabinoids
Glycerides
Male
Rats
Rats, Long-Evans
Receptor, Cannabinoid, CB1
Signal Transduction